HXCX(SZ:300300)2020-04-29 16:00Financial Performance - The company reported a total revenue of 683,136,428 RMB for the year 2018, with a cash dividend of 0.20 RMB per 10 shares distributed to all shareholders[4]. - The company's operating revenue for 2018 was ¥527,647,214.59, representing a 30.48% increase compared to ¥404,385,389.09 in 2017[17]. - The net profit attributable to shareholders for 2018 was ¥124,307,511.26, a 46.00% increase from ¥85,140,455.29 in 2017[17]. - The basic earnings per share for 2018 was ¥0.18, up 50.00% from ¥0.12 in 2017[17]. - The company achieved operating revenue of ¥527,647,214.59, a growth of 30.48% compared to 2017, and a net profit attributable to shareholders of ¥124,307,511.26, an increase of 46.00% year-on-year[39]. - The company reported a total revenue of approximately $790.41 million for the year, with a net profit of $136.32 million, reflecting a significant growth compared to previous periods[100]. Assets and Liabilities - The total assets at the end of 2018 were ¥3,449,022,544.98, reflecting a 1.74% increase from ¥3,389,948,965.54 at the end of 2017[17]. - The net assets attributable to shareholders at the end of 2018 were ¥2,348,035,971.05, a 9.52% increase from ¥2,144,025,573.32 at the end of 2017[17]. - Total operating revenue for 2018 was CNY 527,647,214.59, representing a year-on-year increase of 30.48% compared to CNY 404,385,389.09 in 2017[46]. - The company reported a total external guarantee amount of 11,199.17 million yuan during the reporting period[170]. - The actual guarantee amount at the end of the reporting period was 11,199.17 million yuan, accounting for 4.77% of the company's net assets[170]. Cash Flow - The net cash flow from operating activities for 2018 was ¥28,455,088.65, down 88.00% from ¥237,069,180.91 in 2017[17]. - Operating cash flow for 2018 was ¥28,455,088.65, an 88% decline compared to the previous year, primarily due to increased business promotion expenses[65]. - Investment cash flow net amount increased by 102.46% to ¥14,196,803.76 in 2018, attributed to a decrease in external investments and fixed asset purchases[65]. - Financing cash flow net amount was -¥178,046,359.52, improving by 34.24% from the previous year due to a significant reduction in debt repayment[65]. Market Expansion and Strategy - The company plans to expand its market presence and enhance its product offerings, although specific figures and timelines were not disclosed in the report[4]. - The company plans to continue expanding its market presence and investing in new technologies and products[25]. - The company is focusing on the integration of financing leasing into its smart city business, creating a competitive advantage[27]. - The company is developing a cross-border medical closed-loop system, combining online international consultations and offline overseas medical services[28]. - The company is exploring market expansion opportunities in the medical device sector, particularly in first and second-class medical instruments[79]. - The company has outlined future growth strategies that include market expansion and potential mergers and acquisitions[1]. Investments and Acquisitions - The company acquired a 40% stake in Haoyiyou Medical Technology Group, gaining control and consolidating it into its financial statements[27]. - The company actively engaged in strategic investments, with Aurora Data (stock code: JG) successfully listed on NASDAQ and Weidai (stock code: WEI) listed on the New York Stock Exchange[26]. - The company acquired a 30% stake in Haoyi Medical Technology Co., Ltd. for a total of 54 million CNY[180]. - The company approved the acquisition of 100% equity in Xi'an Huaxin Cinema Co., Ltd. for RMB 12 million and Wuhu Huaxin Cinema Co., Ltd. for RMB 1.4 million[184]. - The company will establish a joint venture, Ningbo Zhenhai Yuyou Interactive Cinema Co., Ltd., with an 80% stake, investing RMB 8 million[184]. Research and Development - The company established a three-tier R&D technical system, enhancing its ability to quickly develop and promote smart city and medical technology products[27]. - The company’s R&D investment for 2018 was ¥32,028,557.16, accounting for 6.07% of total revenue, a significant decrease from 11.68% in 2017[62]. - The number of R&D personnel decreased to 144 in 2018, representing 29.63% of the total workforce, down from 49.00% in 2017[62]. - The company added 7 utility model patents, 31 software copyrights, and 1 software product registration during the reporting period, strengthening its technological innovation capabilities[38]. Risks and Challenges - The company faces risks in new business development, particularly in the smart medical field, which may not meet expectations, necessitating careful monitoring of industry trends and increased R&D investment[108]. - Investment and acquisition risks are present, including potential misvaluation of target companies and operational risks, which require a cautious investment strategy and thorough due diligence[109]. - The company emphasizes the importance of managing accounts receivable, particularly from government and large enterprise clients, to mitigate liquidity and bad debt risks[110]. - The company recognizes the risk of losing core technical and management personnel, which is critical for maintaining its competitive edge in the market[110]. Shareholder Returns and Dividends - The company proposed a cash dividend of RMB 0.20 per 10 shares, totaling RMB 13,662,728.56 for the year 2018[120]. - The cash dividend payout ratio for 2018 was 10.99% of the net profit attributable to ordinary shareholders[123]. - The total distributable profit for the year was RMB 498,377,135.58, with the entire amount allocated for cash dividends[120]. - The company distributed cash dividends of ¥0.196652 per 10 shares, totaling ¥9,002,188.18, and increased capital reserves by issuing 225,054,750 shares[154]. Corporate Governance and Compliance - The company has established a high-efficiency human resources system to support its development needs[114]. - The company is committed to maintaining compliance with regulatory requirements in its financial services operations[1]. - The company has not faced any non-standard audit reports during the reporting period[131]. - The company did not engage in any entrusted financial management or loans during the reporting period[172][173]. Social Responsibility and Environmental Impact - The company reported a significant focus on social responsibility, particularly in poverty alleviation initiatives, although specific metrics were not disclosed[176]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[177].